Bhakay Anagha, Rahman Mahbubur, Dave Rajesh N, Bilgili Ecevit
Otto H. York Department of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA.
Pharmaceutics. 2018 Jul 8;10(3):86. doi: 10.3390/pharmaceutics10030086.
Drug nanoparticles embedded in a dispersant matrix as a secondary phase, i.e., drug-laden nanocomposites, offer a versatile delivery platform for enhancing the dissolution rate and bioavailability of poorly water-soluble drugs. Drug nanoparticles are prepared by top-down, bottom-up, or combinative approaches in the form of nanosuspensions, which are subsequently dried to prepare drug-laden nanocomposites. In this comprehensive review paper, the term “nanocomposites” is used in a broad context to cover drug nanoparticle-laden intermediate products in the form of powders, cakes, and extrudates, which can be incorporated into final oral solid dosages via standard pharmaceutical unit operations, as well as drug nanoparticle-laden strip films. The objective of this paper is to review studies from 2012⁻2017 in the field of drug-laden nanocomposites. After a brief overview of the various approaches used for preparing drug nanoparticles, the review covers drying processes and dispersant formulations used for the production of drug-laden nanocomposites, as well as various characterization methods including quiescent and agitated redispersion tests. Traditional dispersants such as soluble polymers, surfactants, other water-soluble dispersants, and water-insoluble dispersants, as well as novel dispersants such as wet-milled superdisintegrants, are covered. They exhibit various functionalities such as drug nanoparticle stabilization, mitigation of aggregation, formation of nanocomposite matrix⁻film, wettability enhancement, and matrix erosion/disintegration. Major challenges such as nanoparticle aggregation and poor redispersibility that cause inferior dissolution performance of the drug-laden nanocomposites are highlighted. Literature data are analyzed in terms of usage frequency of various drying processes and dispersant classes. We provide some engineering considerations in comparing drying processes, which could account for some of the diverging trends in academia vs. industrial practice. Overall, this review provides rationale and guidance for drying process selection and robust nanocomposite formulation development, with insights into the roles of various classes of dispersants.
作为第二相嵌入分散剂基质中的药物纳米颗粒,即载药纳米复合材料,为提高难溶性药物的溶解速率和生物利用度提供了一个多功能的给药平台。药物纳米颗粒通过自上而下、自下而上或组合方法制备成纳米悬浮液形式,随后干燥以制备载药纳米复合材料。在这篇综述论文中,“纳米复合材料”一词在广义上用于涵盖呈粉末、饼状物和挤出物形式的载药纳米颗粒中间产品,这些产品可通过标准制药单元操作纳入最终口服固体剂型,以及载药条带薄膜。本文的目的是综述2012 - 2017年载药纳米复合材料领域的研究。在简要概述用于制备药物纳米颗粒的各种方法之后,该综述涵盖了用于生产载药纳米复合材料的干燥过程和分散剂配方,以及包括静态和搅拌再分散测试在内的各种表征方法。涵盖了传统分散剂,如可溶性聚合物、表面活性剂、其他水溶性分散剂和水不溶性分散剂,以及新型分散剂,如湿磨超级崩解剂。它们表现出各种功能,如药物纳米颗粒稳定化、聚集减轻、纳米复合材料基质 - 膜形成、润湿性增强以及基质侵蚀/崩解。突出了导致载药纳米复合材料溶解性能较差的主要挑战,如纳米颗粒聚集和再分散性差。根据各种干燥过程和分散剂类别的使用频率分析文献数据。我们在比较干燥过程时提供了一些工程方面的考虑因素,这可以解释学术界与工业实践中一些不同的趋势。总体而言,本综述为干燥过程选择和稳健的纳米复合材料配方开发提供了理论依据和指导,并深入了解了各类分散剂的作用。